The high cost of biologic drugs in Canada has created a demand for biosimilars as a cost-saving alternative for Canadian public health care payers. Several biosimilar products are now commercially available for a variety of conditions, yet, it is suggested that the uptake of biosimilars in Canada remains suboptimal. In order to better understand the current use and uptake of biosimilar products, Canadian policy-makers have requested information on the utilization of biosimilars in various clinical areas, including estimates of any potential cost savings associated with switching policies for biosimilar products. The purpose of this project is to determine the current uptake of biosimilars in Canada for chronic inflammatory conditions, including rheumatoid arthritis and inflammatory bowel disease, in order to support optimization activities in Canadian publicly funded drug programs.
This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies. The Projects in Progress page on the CADTH website is updated on a seven to eight-day cycle. View other current Projects in Progress.